Po Y. Ho

2.1k total citations · 1 hit paper
17 papers, 1.2k citations indexed

About

Po Y. Ho is a scholar working on Immunology, Physiology and Molecular Biology. According to data from OpenAlex, Po Y. Ho has authored 17 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 6 papers in Physiology and 5 papers in Molecular Biology. Recurrent topics in Po Y. Ho's work include Adenosine and Purinergic Signaling (6 papers), Phagocytosis and Immune Regulation (6 papers) and Immunotherapy and Immune Responses (6 papers). Po Y. Ho is often cited by papers focused on Adenosine and Purinergic Signaling (6 papers), Phagocytosis and Immune Regulation (6 papers) and Immunotherapy and Immune Responses (6 papers). Po Y. Ho collaborates with scholars based in United States, India and Israel. Po Y. Ho's co-authors include Irving L. Weissman, Kelly M. McKenna, James Y. Chen, Stephen B. Willingham, Ying Ying Yiu, Kipp Weiskopf, Nan Ring, Sydney Gordon, Aaron M. Ring and Kevin S. Kao and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Po Y. Ho

15 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy

2017 428 citations Amira Barkal, Kipp Weiskopf et al. Nature Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Po Y. Ho United States	7	855	391	337	128	119	17	1.2k
Rachel Weissman-Tsukamoto United States	7	941 1.1×	311 0.8×	324 1.0×	30 0.2×	204 1.7×	9	1.3k
Rachel Brewer United States	3	663 0.8×	315 0.8×	408 1.2×	15 0.1×	67 0.6×	3	1.0k
Jørgen Kjaergäard United States	21	1.4k 1.7×	941 2.4×	430 1.3×	378 3.0×	38 0.3×	28	2.0k
B. Rhodes Ford United States	8	604 0.7×	391 1.0×	249 0.7×	30 0.2×	26 0.2×	10	969
Ailsa J. Christiansen Switzerland	13	240 0.3×	509 1.3×	469 1.4×	18 0.1×	74 0.6×	20	956
Kimberley Stannard Australia	16	1.1k 1.3×	941 2.4×	426 1.3×	358 2.8×	10 0.1×	17	1.6k
Sherly Mardiana Australia	12	824 1.0×	1.2k 3.0×	444 1.3×	110 0.9×	13 0.1×	13	1.5k
Andrea Ponzetta Italy	13	1.2k 1.4×	744 1.9×	352 1.0×	10 0.1×	43 0.4×	21	1.6k
Elio Schouppe Belgium	10	764 0.9×	413 1.1×	274 0.8×	16 0.1×	17 0.1×	12	1.0k
Kevin Sek Australia	8	749 0.9×	935 2.4×	419 1.2×	179 1.4×	12 0.1×	11	1.3k

Countries citing papers authored by Po Y. Ho

Since Specialization

Citations

This map shows the geographic impact of Po Y. Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Po Y. Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Po Y. Ho more than expected).

Fields of papers citing papers by Po Y. Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Po Y. Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Po Y. Ho. The network helps show where Po Y. Ho may publish in the future.

Co-authorship network of co-authors of Po Y. Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Po Y. Ho. A scholar is included among the top collaborators of Po Y. Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Po Y. Ho. Po Y. Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Kenkel, Justin A., Po Y. Ho, Jason Ptacek, et al.. (2023). Abstract 2964: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042. Cancer Research. 83(7_Supplement). 2964–2964. 1 indexed citations

2.

Banuelos, Allison, Dongdong Feng, Kevin S. Kao, et al.. (2021). Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proceedings of the National Academy of Sciences. 118(29). 95 indexed citations

3.

Kenkel, Justin A., Po Y. Ho, Sameera Kongara, et al.. (2021). 862 Dectin-2, a novel target for tumor macrophage reprogramming in cancer immunotherapy. Regular and Young Investigator Award Abstracts. A903–A903.

4.

Leblanc, Heidi, Cecelia I. Pearson, Justin A. Kenkel, et al.. (2020). 605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models. SHILAP Revista de lepidopterología. A361–A362. 5 indexed citations

5.

Ackerman, Shelley E., Felix J. Hartmann, Cecelia I. Pearson, et al.. (2020). 603 Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration. SHILAP Revista de lepidopterología. A360.1–A360. 1 indexed citations

6.

Willingham, Stephen B., Po Y. Ho, Andrew Hotson, et al.. (2018). A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models. Cancer Immunology Research. 6(10). 1136–1149. 162 indexed citations

7.

Betancur, Paola, Brian J. Abraham, Ying Ying Yiu, et al.. (2017). A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nature. 1 indexed citations

8.

Willingham, Stephen B., Andrew Hotson, Po Y. Ho, et al.. (2017). Abstract 5593: Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies. Cancer Research. 77(13_Supplement). 5593–5593. 1 indexed citations

9.

Betancur, Paola, Brian J. Abraham, Ying Ying Yiu, et al.. (2017). A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nature Communications. 8(1). 14802–14802. 178 indexed citations

10.

Ho, Po Y., et al.. (2017). Abstract 5598: Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models. Cancer Research. 77(13_Supplement). 5598–5598. 1 indexed citations

11.

Barkal, Amira, Kipp Weiskopf, Kevin S. Kao, et al.. (2017). Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology. 19(1). 76–84. 428 indexed citations breakdown →

12.

Chhabra, Akanksha, Aaron M. Ring, Kipp Weiskopf, et al.. (2016). Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Science Translational Medicine. 8(351). 351ra105–351ra105. 121 indexed citations

13.

Willingham, Stephen B., Po Y. Ho, Robert D. Leone, et al.. (2016). Adenosine A2A receptor antagonist, CPI-444, blocks adenosine-mediated T cell suppression and exhibits anti-tumor activity alone and in combination with anti-PD-1 and anti-PD-L1. Annals of Oncology. 27. vi366–vi366. 2 indexed citations

14.

Willingham, Stephen B., Andrew Hotson, Po Y. Ho, et al.. (2016). Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies. Cancer Immunology Research. 4(11_Supplement). PR04–PR04. 7 indexed citations

15.

Willingham, Stephen B., Po Y. Ho, Robert D. Leone, et al.. (2016). Abstract 2337: The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1. Cancer Research. 76(14_Supplement). 2337–2337. 4 indexed citations

16.

Feng, Mingye, James Y. Chen, Rachel Weissman-Tsukamoto, et al.. (2015). Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk. Proceedings of the National Academy of Sciences. 112(7). 2145–2150. 211 indexed citations

17.

Chhabra, Akanksha, Aaron M. Ring, Kipp Weiskopf, et al.. (2015). HSC transplantation in an immunocompetent host without radiation or chemotherapy. Experimental Hematology. 43(9). S57–S57. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact